Merck ’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study

< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Results to be Presented at Future Medical Meeting, and Regulatory Submissions Planned for 2016 < /p > < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced top-line results from the company ’s Phase 3 pivotal
trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily
formulation of ISENTRESS < sup > ® < /sup > < b > < /b > (raltegravir), known as
raltegravir 600 mg (to be given as 2 x 600 mg once-daily), for
previously untreated HIV-1 infected adults. < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressreleaselanguage " > < div class= " field-label " > Language: < /div > < div class= " field-items " > < div class= " field-item odd " >
English < /div > < /div > < /div > < div class= " field field-type-text field-field-pre...

Source: Merck.com - Research and Development News - February 22, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ISENTRESS NYSE:MRK Source Type: news